Holen Sie sich die Stockscreener-App
4.25
4.94%
0.20
Handel nachbörslich:
4.26
0.010
+0.24%
Schlusskurs vom Vortag:
$4.05
Offen:
$4.04
24-Stunden-Volumen:
47,486
Relative Volume:
0.47
Marktkapitalisierung:
$241.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.86M
KGV:
-3.5417
EPS:
-1.2
Netto-Cashflow:
$-58.82M
1W Leistung:
+8.28%
1M Leistung:
+13.64%
6M Leistung:
-17.95%
1J Leistung:
+4.94%
1-Tages-Spanne:
$4.04
$4.26
1-Wochen-Bereich:
$3.945
$4.34
52-Wochen-Spanne:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Vergleichen Sie DSGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
4.25 | 222.82M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
What drives Design Therapeutics Inc. stock priceBreakthrough stock performance - jammulinksnews.com
Design Therapeutics Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com
Is Design Therapeutics Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
What drives AORT stock priceExceptional market positioning - PrintWeekIndia
Is Laureate Education Inc. a good long term investmentPhenomenal capital gains - Autocar Professional
What analysts say about Design Therapeutics Inc. stockTriple-digit wealth increases - printweek.in
Best Indian Stocks for Portfolio Protection AI Recommended Market StrategiesPhenomenal wealth increase - jammulinksnews.com
What analysts say about SBXC WS stockOutstanding capital appreciation - jammulinksnews.com
Is Design Therapeutics Inc. stock a growth or value playFree Membership Group - Newser
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 3.1% – Should You Sell? - Defense World
Why Design Therapeutics Inc. stock attracts strong analyst attentionDefensive Stock Picks with Upside - beatles.ru
Why Synaptogenix Inc. stock attracts strong analyst attentionSecure Your Capital Strategy - Newser
What makes Design Therapeutics Inc. stock price move sharplyDaily Breakout Picks - Newser
How SIMAU stock performs during market volatilityFast Moving Stock Alerts - Newser
Why Sionna Therapeutics Inc. stock attracts strong analyst attentionFree VIP Investment Strategies - Newser
How Design Therapeutics Inc. stock performs during market volatilityElite Stock Shortlist - Newser
High-Potential Biotech Penny Stocks in 2025: ProKidney and Design Therapeutics Lead the Way - AInvest
Penny Stocks To Watch In July 2025 - simplywall.st
Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest
BioVie Highlights Patient-Centric Design of SUNRISE-PD - GlobeNewswire
FDA Boosts CERo's Revolutionary T Cell Therapy with Orphan Drug Status for Deadly Blood Cancer - Stock Titan
Design Therapeutics Confirms Directors at Annual Meeting - TipRanks
Design Therapeutics reports voting results from annual meeting - Investing.com
Squarepoint Ops LLC Has $297,000 Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - The Malaysian Reserve
BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Nuveen Asset Management LLC Sells 54,550 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Two Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Design Therapeutics starts Friedreich ataxia patient trial By Investing.com - Investing.com South Africa
Transcript : Design Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com
RBC Capital maintains Design Therapeutics stock rating with $5 target - Investing.com Australia
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):